Vivien Maud, Deberles Emilie, Morello Remy, Haddouche Aimi, Guenet David, Reznik Yves
Department of Endocrinology, CHU Côte de Nacre, Caen, France.
Department of Clinical Research and Statistics, CHU Côte de Nacre, Caen, France.
Horm Metab Res. 2019 Mar;51(3):172-177. doi: 10.1055/a-0857-1620. Epub 2019 Mar 12.
The diagnostic workup for primary aldosteronism includes a screening step using the aldosterone-to-renin ratio (ARR) and a confirmatory step based on dynamic testing of aldosterone secretion autonomy. International guidelines suggest that precise clinical and biochemical conditions may allow the bypassing of the confirmatory step, however, data which validate hormone thresholds defining such conditions are lacking. At our tertiary center, we retrospectively examined a cohort of 173 hypertensive patients screened for PA by the ARR, of whom 120 had positive screening and passed a saline infusion test (SIT) or a captopril challenge test (CCT). Fifty-nine had PA, including 34 Conn adenomas and 25 with idiopathic aldosteronism (IA). Using a threshold of 160 pmol/l, post-SIT plasma aldosterone concentration (PAC) identified PA with 86.4% sensitivity, 94.7% specificity, and a negative predictive value of 92.3%. Of those subjects with a high ARR and a PAC above 550 pmol/l, 93% had a positive SIT, while 100% of subjects with a high ARR, but a PAC under 240 pmol/l had a negative SIT. Our results thus validate the biochemical conditions defined in the French and US guidelines for bypassing the confirmatory step in the workup for PA diagnosis.
原发性醛固酮增多症的诊断检查包括使用醛固酮与肾素比值(ARR)进行筛查的步骤以及基于醛固酮分泌自主性动态检测的确诊步骤。国际指南表明,精确的临床和生化条件可能允许跳过确诊步骤,然而,缺乏验证定义此类条件的激素阈值的数据。在我们的三级中心,我们回顾性研究了一组173例通过ARR筛查原发性醛固酮增多症的高血压患者,其中120例筛查呈阳性并通过了生理盐水输注试验(SIT)或卡托普利激发试验(CCT)。59例患有原发性醛固酮增多症,包括34例Conn腺瘤和25例特发性醛固酮增多症(IA)。以160 pmol/l为阈值,SIT后血浆醛固酮浓度(PAC)诊断原发性醛固酮增多症的灵敏度为86.4%,特异度为94.7%,阴性预测值为92.3%。在那些ARR高且PAC高于550 pmol/l的受试者中,93%的SIT呈阳性,而在那些ARR高但PAC低于240 pmol/l的受试者中,100%的SIT呈阴性。因此,我们的结果验证了法国和美国指南中定义的生化条件,即在原发性醛固酮增多症诊断检查中可跳过确诊步骤。